Orforglipron: separating real trial data from TikTok hype

What did @onthepen.official actually say?

The creator called orforglipron a "big miss," claiming the highest dose of 36 mg produced about 9% placebo-adjusted weight loss over 72 weeks, compared to roughly 16% with injectable semaglutide (Wegovy). The conclusion: orforglipron "way missed the mark" and isn't close to tirzepatide either.

This is a reasonably specific claim grounded in actual trial data, which is more than most TikTok health takes manage. The creator is referencing real numbers from what appears to be a Phase 2 or Phase 3 readout from Eli Lilly's orforglipron program. The comparison to Wegovy and tirzepatide is a fair framing question, even if the analysis needs some nuance added to it.

Does the science back this up?

Mostly, yes. But the 9% figure deserves more context before anyone calls it a failure. The Phase 3 ATTAIN trial data, and earlier Phase 2 data published in the New England Journal of Medicine (Wharton et al., 2023), showed orforglipron at its highest doses achieving placebo-adjusted weight loss in the range of 8-9% over roughly 36 weeks in Phase 2. Extended Phase 3 data at 72 weeks does appear to land in that same general range for the 36 mg dose.

For comparison, the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg producing approximately 14.9% placebo-adjusted weight loss over 68 weeks. Tirzepatide at its highest dose in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) reached about 20.9% placebo-adjusted loss. So the gap is real. Orforglipron is trailing both, at least by these headline numbers.

What did they get wrong (or right)?

The creator got the directional story right: orforglipron underperforms injectable semaglutide on weight loss, and it is not in the same league as tirzepatide. That part is accurate. Where it gets sloppy is treating this as a simple head-to-head loss.

These are not the same patient populations, trial durations, or endpoints, so direct percentage comparisons are imprecise. More importantly, orforglipron is an oral, once-daily pill, not an injectable. The relevant comparison for many patients would be oral semaglutide (Rybelsus), which shows modest weight loss in the range of 3-5% in clinical settings. Against that bar, orforglipron looks considerably more competitive.

The creator also mispronounces the drug name repeatedly, calling it "forgopron" at points, which is a minor credibility issue but not a factual one. Calling this a "big miss" is an editorial judgment that may reflect investor expectations more than clinical reality.

What should you actually know?

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Because it is not a peptide, it survives oral digestion without the absorption tricks needed by semaglutide tablets. That is a genuine pharmacological advantage. If it clears regulatory approval, it would be the first oral GLP-1 that does not require the strict fasting and timing requirements of Rybelsus.

Nine percent placebo-adjusted weight loss over 72 weeks is not nothing. For context, older obesity drugs that were once considered effective, like orlistat, produced around 3% placebo-adjusted loss. The question for patients and clinicians is not just "how does it compare to Wegovy" but "how does it compare to taking nothing, or to oral options currently available."

Eli Lilly's full Phase 3 data package has not been published in peer-reviewed form as of this writing. Judging a drug's clinical value from trial readout headlines is a known source of premature conclusions, in both directions.